I think if there was an adverse event, even in this lesser trial, it would require reporting and analysis as it is impacting patients. Management could not release what has been released and be so confident if there were unresolved safety issues IMO.
Ann: Encouraging Initial Data from CYP-006TK DFU Trial, page-39
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 25.0¢ | $3.097K | 12.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29341 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 11015 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |